Vaxcyte Inc. (PCVX)
undefined
undefined%
At close: undefined
87.72
-0.02%
After-hours Dec 13, 2024, 05:19 PM EST

Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.

Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.

The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis.

The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.

Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte Inc.
Vaxcyte Inc. logo
Country United States
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 254
CEO Grant E. Pickering M.B.A.

Contact Details

Address:
825 Industrial Road
San Carlos, California
United States
Website https://vaxcyte.com

Stock Details

Ticker Symbol PCVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001649094
CUSIP Number 92243G108
ISIN Number US92243G1085
Employer ID 46-4233385
SIC Code 2836

Key Executives

Name Position
Grant E. Pickering M.B.A. Co-Founder, Chief Executive Officer & Director
Andrew L. Guggenhime M.B.A. President & Chief Financial Officer
James Wassil M.B.A., M.S. Executive Vice President & Chief Operating Officer
Whitney Jones Chief People Officer
Dr. Ashish Khanna M.B.A., Ph.D. Co-Founder
Dr. Jeff Fairman Ph.D. Co-Founder & Vice President of Research
Elvia Cowan Senior Vice President of Finance & Principal Accounting Officer
Janet Graesser Senior Vice President of Corporate Communications & Investor Relations
Mikhail Eydelman J.D. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
Paul W. Sauer M.B.A. Senior Vice President of Process Development & Manufacturing

Latest SEC Filings

Date Type Title
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 09, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Nov 21, 2024 8-K Current Report
Nov 19, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...